Download PDF
Horm Metab Res 2013; 45(06): 423-429
DOI: 10.1055/s-0033-1333751
Original Basic
© Georg Thieme Verlag KG Stuttgart · New York

17β-Estradiol Suppresses the Macrophage Foam Cell Formation Associated with SOCS3

X. Liang
1   Department of Cardiovascular Medicine, First Affiliated Hospital of Medical School, Xi’an Jiaotong University, Xi’an, Shaanxi, P. R. China
,
M. He
1   Department of Cardiovascular Medicine, First Affiliated Hospital of Medical School, Xi’an Jiaotong University, Xi’an, Shaanxi, P. R. China
,
T. Chen
1   Department of Cardiovascular Medicine, First Affiliated Hospital of Medical School, Xi’an Jiaotong University, Xi’an, Shaanxi, P. R. China
,
Y. Wu
1   Department of Cardiovascular Medicine, First Affiliated Hospital of Medical School, Xi’an Jiaotong University, Xi’an, Shaanxi, P. R. China
,
Y. Tian
1   Department of Cardiovascular Medicine, First Affiliated Hospital of Medical School, Xi’an Jiaotong University, Xi’an, Shaanxi, P. R. China
,
Y. Zhao
1   Department of Cardiovascular Medicine, First Affiliated Hospital of Medical School, Xi’an Jiaotong University, Xi’an, Shaanxi, P. R. China
,
Y. Shen
1   Department of Cardiovascular Medicine, First Affiliated Hospital of Medical School, Xi’an Jiaotong University, Xi’an, Shaanxi, P. R. China
,
Y. Liu
1   Department of Cardiovascular Medicine, First Affiliated Hospital of Medical School, Xi’an Jiaotong University, Xi’an, Shaanxi, P. R. China
,
Z. Yuan
1   Department of Cardiovascular Medicine, First Affiliated Hospital of Medical School, Xi’an Jiaotong University, Xi’an, Shaanxi, P. R. China
2   Key Laboratory of Environment and Genes Related to Diseases, Xi’an Jiaotong University, Ministry of Education, Xi’an, Shaanxi, P. R. China
3   Key Laboratory of Molecular Cardiology, Xi’an Jiaotong University, Xi'an, Shaanxi, P. R. China
› Author Affiliations
Further Information

Publication History

received 18 July 2012

accepted 10 January 2013

Publication Date:
21 February 2013 (online)

Also available at
    Permissions and Reprints

Abstract

Evidence from clinical trials and animal experiments has shown that estrogen has anti-atherosclerotic effects when administered to young women or experimental animals. The mechanisms involve the modulation of vascular inflammation, growth factor expression, and oxidative stress injured arteries. However, whether estrogen modulates the foam cell formation in plaque remains unknown. Here, we investigated the effects of 17β-estradiol (E2) on cholesterol efflux in vivo and in vitro. ApoE null mice underwent an ovariectomy at 5th week of age and then were treated with E2 or vehicle for the following 8 weeks. Compared with the vehicle-treated mice, the serum total cholesterol level, atherosclerotic plaque size, and lipid deposits were decreased and meanwhile ATP-binding cassette transporter A1 (ABCA1) expression in the plaque was increased in mice with E2 treatment. E2 also increased suppressor of cytokine signaling 3 (SOCS3) expression in the atherosclerotic plaques and in RAW264.7 cells. In vitro, E2 treatment reversed janus kinase/signal transducers and activators of transcription (JAK/STAT)-inhibited ABCA1 expression in RAW264.7 cells but had no effect on ABCA1 expression in SOCS3 knockdown cells. SOCS3 overexpression elevated ABCA1 expression through the inhibition of JAK2/STAT3 phosphorylation. Finally, we also found that E2 enhanced the cholesterol efflux to apoA I in RAW264.7 cells. In summary, E2 reduces atherosclerosis in ApoE null mice associated with upregulating ABCA1 expression and modulating the cholesterol efflux, which are dependent on SOCS3 upregulation. These results provide new insight into the athero-protective effects of estrogen.

Key words

estrogens - estrogen receptors - foam cells - ABCA1 - SOCS3

Supporting Information

    for this article is available online at http://www.thieme-connect.de/ejournals/toc/hmr.
  • Supporting Information
 

  • References

  • 1 Barrett-Connor E. Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. Circulation 1997; 95: 252-264
    CrossrefPubMedGoogle Scholar
  • 2 Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, Selzer RH, Liu Cr CR, Liu Ch CH, Azen SP. Estrogen in the Prevention of Atherosclerosis Trial Research Group. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 135: 939-953
    CrossrefPubMedGoogle Scholar
  • 3 Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses’ health study. N Engl J Med 1991; 325: 756-762
    CrossrefPubMedGoogle Scholar
  • 4 Marsh MM, Walker VR, Curtiss LK, Banka CL. Protection against atherosclerosis by estrogen is independent of plasma cholesterol levels in LDL receptor-deficient mice. J Lipid Res 1999; 40: 893-900
    PubMedGoogle Scholar
  • 5 Bourassa PA, Milos PM, Gaynor BJ, Breslow JL, Aiello RJ. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 1996; 93: 10022-10027
    CrossrefPubMedGoogle Scholar
  • 6 Liao Q, Li X, Zhou S, Liu L, Zhao S, Lian Y, Dong H. Estrogen treatment inhibits vascular endothelial senescence and asymmetrical dimethylarginine in ovariectomized rabbits. J Cardiovasc Pharmacol 2011; 57: 174-182
    CrossrefPubMedGoogle Scholar
  • 7 Kavanagh K, Davis MA, Zhang L, Wilson MD, Register TC, Adams MR, Rudel LL, Wagner JD. Estrogen decreases atherosclerosis in part by reducing hepatic acyl-CoA:cholesterol acyltransferase 2 (ACAT2) in monkeys. Arterioscler Thromb Vasc Biol 2009; 29: 1471-1477
    CrossrefPubMedGoogle Scholar
  • 8 Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-613
    CrossrefPubMedGoogle Scholar
  • 9 Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Writing Group for the Women’s Health Initiative Investigators . . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333
    CrossrefPubMed
  • 10 Kolovou G, Giannakopoulou V, Vasiliadis Y, Bilianou H.. Effects of estrogens on atherogenesis. Curr Vasc Pharmacol 2011; 9: 244-257
    CrossrefPubMedGoogle Scholar
  • 11 Billon-Galés A, Fontaine C, Douin-Echinard V, Delpy L, Berges H, Calippe B, Lenfant F, Laurell H, Guéry JC, Gourdy P, Arnal JF.. Endothelial estrogen receptor-alpha plays a crucial role in the atheroprotective action of 17beta-estradiol in low-density lipoprotein receptor-deficient mice. Circulation 2009; 120: 2567-2576
    CrossrefPubMedGoogle Scholar
  • 12 Srivastava RA.. Estrogen-induced regulation of the ATP-binding cassette transporter A1 (ABCA1) in mice: a possible mechanism of atheroprotection by estrogen. Mol Cell Biochem 2002; 240: 67-73
    CrossrefPubMedGoogle Scholar
  • 13 Darabi M, Rabbani M, Ani M, Zarean E, Panjehpour M, Movahedian A. Increased leukocyte ABCA1 gene expression in post-menopausal women on hormone replacement therapy. Gynecol Endocrinol 2011; 27: 701-705
    CrossrefPubMedGoogle Scholar
  • 14 Chakrabarti S, Lekontseva O, Davidge ST.. Estrogen is a modulator of vascular inflammation. IUBMB Life 2008; 60: 376-382
    CrossrefPubMedGoogle Scholar
  • 15 Zhao SP, Dong SZ. Effect of tumor necrosis factor alpha on cholesterol efflux in adipocytes. Clin Chim Acta 2008; 389: 67-71
    CrossrefPubMedGoogle Scholar
  • 16 Li Y, Schwabe RF, DeVries-Seimon T, Yao PM, Gerbod-Giannone MC, Tall AR, Davis RJ, Flavell R, Brenner DA, Tabas I.. Free cholesterol-loaded macrophages are an abundant source of tumor necrosis factor-alpha and interleukin-6: model of NF-kappaB- and map kinase-dependent inflammation in advanced atherosclerosis. J Biol Chem 2005; 280: 21763-21772
    CrossrefPubMedGoogle Scholar
  • 17 Reiss AB, Patel CA, Rahman MM, Chan ES, Hasneen K, Montesinos MC, Trachman JD, Cronstein BN.. Interferon-gamma impedes reverse cholesterol transport and promotes foam cell transformation in THP-1 human monocytes/macrophages. Med Sci Monit 2004; 10: 420-425
    PubMedGoogle Scholar
  • 18 Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ.. A family of cytokine-inducible inhibitors of signalling. Nature 1997; 387: 917-921
    CrossrefPubMedGoogle Scholar
  • 19 Tamiya T, Kashiwagi I, Takahashi R, Yasukawa H, Yoshimura A.. Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: regulation of T-cell inflammation by SOCS1 and SOCS3. Arterioscler Thromb Vasc Biol 2011; 31: 980-985
    CrossrefPubMedGoogle Scholar
  • 20 Yoshimura A, Naka T, Kubo M.. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007; 7: 454-465
    CrossrefPubMedGoogle Scholar
  • 21 Xue JH, Yuan Z, Wu Y, Liu Y, Zhao Y, Zhang WP, Tian YL, Liu WM, Liu Y, Kishimoto C.. High glucose promotes intracellular lipid accumulation in vascular smooth muscle cells by impairing cholesterol influx and efflux balance. Cardiovasc Res 2010; 86: 141-150
    CrossrefPubMedGoogle Scholar
  • 22 Davidson MH, Maki KC, Marx P, Maki AC, Cyrowski MS, Nanavati N, Arce JC.. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch Intern Med 2000; 160: 3315-3325
    CrossrefPubMedGoogle Scholar
  • 23 Davidson MH, Maki KC, Marx P, Maki AC, Cyrowski MS, Nanavati N, Arce JC.. 17 beta-estradiol prevents fatty streak formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 1997; 17: 2679-2684
    CrossrefPubMedGoogle Scholar
  • 24 Lundholm L, Movérare S, Steffensen KR, Nilsson M, Otsuki M, Ohlsson C, Gustafsson JA, Dahlman-Wright K.. Gene expression profiling identifies liver X receptor alpha as an estrogen-regulated gene in mouse adipose tissue. J Mol Endocrinol 2004; 32: 879-892
    CrossrefPubMedGoogle Scholar
  • 25 Hao XR, Cao DL, Hu YW, Li XX, Liu XH, Xiao J, Liao DF, Xiang J, Tang CK.. IFN-gamma down-regulates ABCA1 expression by inhibiting LXRalpha in a JAK/STAT signaling pathway-dependent manner. Atherosclerosis 2009; 203: 417-428
    CrossrefPubMedGoogle Scholar
  • 26 Mo ZC, Xiao J, Liu XH, Hu YW, Li XX, Yi GH, Wang Z, Tang YL, Liao DF, Tang CK.. AOPPs inhibits cholesterol efflux by down-regulating ABCA1 expression in a JAK/STAT signaling pathway-dependent manner. J Atheroscler Thromb 2011; 18: 796-807
    CrossrefPubMedGoogle Scholar
  • 27 Frisdal E, Lesnik P, Olivier M, Robillard P, Chapman MJ, Huby T, Guerin M, Le Goff W. Interleukin-6 protects human macrophages from cellular cholesterol accumulation and attenuates the proinflammatory response. J Biol Chem 2011; 286: 30926-30936
    CrossrefPubMedGoogle Scholar
  • 28 Adhikari N, Charles N, Lehmann U, Hall JL. Transcription factor and kinase-mediated signaling in atherosclerosis and vascular injury. Curr Atheroscler Rep 2006; 8: 252-260
    CrossrefPubMedGoogle Scholar
  • 29 Gharavi NM, Alva JA, Mouillesseaux KP, Lai C, Yeh M, Yeung W, Johnson J, Szeto WL, Hong L, Fishbein M, Wei L, Pfeffer LM, Berliner JA. Role of the Jak/STAT pathway in the regulation of interleukin-8 transcription by oxidized phospholipids in vitro and in atherosclerosis in vivo. J Biol Chem 2007; 282: 31460-31468
    CrossrefPubMedGoogle Scholar
  • 30 Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, Krishnaswami S, Burgos-Vargas R, Wilkinson B, Zerbini CA, Zwillich SH. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009; 60: 1895-1905
    CrossrefPubMedGoogle Scholar
  • 31 Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W. Study A3921063 Investigators. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367: 616-624
    CrossrefPubMedGoogle Scholar
  • 32 Leung KC, Doyle N, Ballesteros M, Sjogren K, Watts CK, Low TH, Leong GM, Ross RJ, Ho KK.. Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proc Natl Acad Sci USA 2003; 100: 1016-1021
    CrossrefPubMedGoogle Scholar
  • 33 Leong GM, Moverare S, Brce J, Doyle N, Sjögren K, Dahlman-Wright K, Gustafsson JA, Ho KK, Ohlsson C, Leung KC.. Estrogen up-regulates hepatic expression of suppressors of cytokine signaling-2 and -3 in vivo and in vitro. Endocrinology 2004; 145: 5525-5531
    CrossrefPubMedGoogle Scholar
  • 34 Tomoka Yamamoto Hideo, Yasukawa Mitsuhisa, Koga Yusuke, Sugi Daisuke, Fukui Nobuyoshi, Futamata Nobuhiro, Tahara Hisashi. Kai, Tsutomu Imaizumi. Abstract 911: Lacking SOCS3 Gene in Macrophages Prevents the Development of Atherosclerosis in ApoE Deficient Mice. Circulation. 2007 116: II_179
    PubMedGoogle Scholar
  • 35 Ortiz-Muñoz G, Martin-Ventura JL, Hernandez-Vargas P, Mallavia B, Lopez-Parra V, Lopez-Franco O, Muñoz-Garcia B, Fernandez-Vizarra P, Ortega L, Egido J, Gomez-Guerrero C. Suppressors of cytokine signaling modulate JAK/STAT-mediated cell responses during atherosclerosis. Arterioscler Thromb Vasc Biol 2009; 29: 525-531
    CrossrefPubMedGoogle Scholar